UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit. Most likely, the UK is the best environment for putting forward trials that are properly…
Taiwan Ken-Shwo Dai, president and CEO of Visgeneer, explains his biotech’s expertise in medtech, skincare, gene therapy and diagnostics, as well as his plans to take the company public. Can you introduce yourself and Visgeneer to our readers? What have been the main milestones for the company so far? “Visgeneer believes that…
Pharma Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and MolMed. Can you please give our readers a brief rundown of the history of MolMed since its foundation in 1996?…
See our Cookie Privacy Policy Here
